Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $40 from $45 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cathie Wood Loads Up on Klarna, Synopsys, and Rubrik, Trims Shopify and Roblox Stocks
- Cathie Wood’s ARK Investment buys 221.7K shares of Twist Bioscience today
- PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
- Cathie Wood’s ARK Investment buys 47.7K shares of Twist Bioscience today
- Twist Bioscience announces collaboration with Synthetic Design Lab